MedTrace Logo

Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma

NCT00431210 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2017-04-18

No results posted yet for this study

Summary

The purpose of this study is to determine the safety of making and giving Epstein-Barr virus (EBV) immunotherapy products to subjects with nasopharyngeal carcinoma (NPC) associated with EBV that has come back or spread to other parts of the body. EBV immunotherapy product is made with white blood cells from the participants body that are collected intravenously. This EBV immunotherapy product may stop cancer cells from growing abnormally. EBV immunotherapy products have been used in several research studies for NPC. Information from these studies suggests the EBV immunotherapy products may stop the growth of NPC in some subjects.

Conditions

  • Nasopharyngeal Carcinoma

Interventions

BIOLOGICAL

Epstein-Barr virus-specific adoptive T-cells immunotherapy

Given intravenously on Day 1 and Day 14

Sponsors & Collaborators

Principal Investigators

  • Jochen Lorch, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2015-06-30
Completion
2016-01-26

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00431210 on ClinicalTrials.gov